Publications

The publications of Prof. Thaçi and our scientists can be found on PubMed.gov.

Our scientists: 

  • Dr. rer. nat. Yask Gupta - Genetic & Computational biology (AG Thaçi / AG Sezin)
  • Dr. Marlena Hawro
  • prof. (Prof.) Dr. med. Tomasz Hawro
  • Dr. rer. nat. Tatiana Sezin - Immunology, Spatial & single cell transcriptomics, Microbiome, Human genetics (AG Sezin)
  • PD Dr. med. Sascha Ständer
  • Dr. rer. nat. Henner Zirpel - Forschungsleitung Cluster

The following list contains a selection of publications:

 

Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease

Gupta Y, Friedman DJ, McNulty MT, Khan A, Lane B, Wang C, Ke J, Jin G, Wooden B, Knob AL, Lim TY, Appel GB, Huggins K, Liu L, Mitrotti A, Stangl MC, Bomback A, Westland R, Bodria M, Marasa M, Shang N, Cohen DJ, Crew RJ, Morello W, Canetta P, Radhakrishnan J, Martino J, Liu Q, Chung WK, Espinoza A, Luo Y, Wei WQ, Feng Q, Weng C, Fang Y, Kullo IJ, Naderian M, Limdi N, Irvin MR, Tiwari H, Mohan S, Rao M, Dube GK, Chaudhary NS, Gutiérrez OM, Judd SE, Cushman M, Lange LA, Lange EM, Bivona DL, Verbitsky M, Winkler CA, Kopp JB, Santoriello D, Batal I, Pinheiro SVB, Oliveira EA, Simoes E Silva AC, Pisani I, Fiaccadori E, Lin F, Gesualdo L, Amoroso A, Ghiggeri GM, D'Agati VD, Magistroni R, Kenny EE, Loos RJF, Montini G, Hildebrandt F, Paul DS, Petrovski S, Goldstein DB, Kretzler M, Gbadegesin R, Gharavi AG, Kiryluk K, Sampson MG, Pollak MR, Sanna-Cherchi S

Veröffentlicht in Nature Communications im November 2023

Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study

Kridin K, Zirpel H, Mruwat N, Ludwig RJ, Thaci D.

Veröffentlicht im Journal of the European Academy of Dermatology and Venereology im November 2023

Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study

Olbrich H, Kridin K, Zirpel H, Sadik CD, Terheyden P, Thaçi D, Ludwig RJ, Boch K.

Veröffentlicht im eBioMedicine im Juli 2023

Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria

Terhorst-Molawi D,* Hawro T,* Grekowitz E, Kiefer L, Merchant K, Alvarado D, Thomas LJ, Hawthorne T, Crowley E, Heath-Chiozzi M, Metz M, Maurer M.

Veröffentlicht in Allergy im Mai 2023

Mortality in eight autoimmune bullous diseases: A global large-scale retrospective cohort study

Boch K, Zirpel H, Thaci D, Mruwat N, Zillikens D, Ludwig RJ, Kridin K

Veröffentlicht im Journal of the European Academy of Dermatology and Venereology im April 2023

Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome

Barry A*, McNulty MT*, Jia X*, Gupta Y*, Debiec H, Luo Y, Nagano C, Horinouchi T, Jung S, Colucci M, Ahram DF, Mitrotti A, Sinha A, Teeninga N, Jin G, Shril S,Caridi G, Bodria M, Lim TY, Westland R, Zanoni F, Marasa M, Turudic D, Giordano M, Gesualdo L, Magistroni R, Pisani I, Fiaccadori E, Reiterova J, Maringhini S, Morello W, Montini G, Weng PL, Scolari F, Saraga M, Tasic V, Santoro D, van Wijk JAE, Milošević D, Kawai Y, Kiryluk K, Pollak MR, Gharavi A, Lin F, Simœs E Silva AC, Loos RJF, Kenny EE, Schreuder MF, Zurowska A, Dossier C, Ariceta G, Drozynska-Duklas M, Hogan J, Jankauskiene A, Hildebrandt F, Prikhodina L, Song K, Bagga A, Cheong H 2nd, Ghiggeri GM, Vachvanichsanong P, Nozu K, Lee D, Vivarelli M, Raychaudhuri S, Tokunaga K, Sanna-Cherchi S, Ronco P, Iijima K, Sampson MG.

Veröffentlicht in Nature Communications im April 2023.

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators.

Veröffentlicht im New England Journal of Medicine im März 2023

Contamination source modeling with SCRuB improves cancer phenotype prediction from microbiome data

Austin GI, Park H, Meydan Y, Seeram D, Sezin T, Lou YC, Firek BA, Morowitz MJ, Banfield JF, Christiano AM, Pe'er I, Uhlemann AC, Shenhav L*, Korem T*.

Veröffentlicht in Nature Biotechnology im März 2023

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial

Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B.

Veröffentlicht im Journal of the American Academy of Dermatology im Februar 2023

Impact of diet and host genetics on the murine intestinal mycobiome

Gupta Y, Ernst AL, Vorobyev A, Beltsiou F, Zillikens D, Bieber K, Sanna-Cherchi S, Christiano AM, Sadik CD, Ludwig RJ, Sezin T.

Veröffentlicht in Nature Communications im Februar 2023

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Merola JF, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Gottlieb AB, Thaçi D, Warren RB, Ink B, Assudani D, Bajracharya R, Shende V, Coarse J, Coates LC.

Veröffentlicht im Lancet im Januar 2023

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A.

Veröffentlicht im Journal of the American Academy of Dermatology im Januar 2023

Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness

Nicolescu AC, Ionescu MA, Constantin MM, Ancuta I, Ionescu S, Niculet E, Tatu AL, Zirpel H, Thaçi D.

Veröffentlicht in Life (Basel) im Dezember 2022

A comprehensive, tri-national, cross-sectional analysis of characteristics and impact of pruritus in psoriasis

Hawro M, Sahin E, Steć M, Różewicka-Czabańska M, Raducha E, Garanyan L, Philipp S, Kokolakis G, Christou D, Kolkhir P, Pogorelov D, Weller K, Metz M, Sabat R, Maleszka R, Olisova O, Maurer M, Hawro T.

Veröffentlicht im Journal of the European Academy of Dermatology and Venereology im November 2022

Case report: Clinical features of COVID-19 vaccine-induced exacerbation of psoriasis-A case series and mini review.

Sascha Ständer, Henner Zirpel, Florin Bujoreanu, Alin Laurentiu Tatu, Ralf J Ludwig, Diamant Thaçi

veröffentlicht im Frontiers in Medicine im September 2022.

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.

April W Armstrong, Melinda Gooderham, Richard B Warren, Kim A Papp, Bruce Strober, Diamant Thaçi, Akimichi Morita, Jacek C Szepietowski, Shinichi Imafuku, Elizabeth Colston, John Throup, Sudeep Kundu, Steve Schoenfeld, Misti Linaberry, Subhashis Banerjee, Andrew Blauvelt.

veröffentlicht im Journal of the American Academy of Dermatology im Juli 2022.

Prevalence and factors associated with sleep disturbance in adult patients with psoriasis

Sahin E, Hawro M, Weller K, Sabat R, Philipp S, Kokolakis G, Christou D, Metz M, Maurer M, Hawro T

Veröffentlicht im Journal of the European Academy of Dermatology and Venereology im Mai 2022

Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.

D Thaçi, K Eyerich, A Pinter, M Sebastian, K Unnebrink, S Rubant, D A Williams, P Weisenseel.

veröffentlicht im British Journal of Dermatology im Januar 2022.

Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors

Spindler M, Przybyłowicz K, Hawro M, Weller K, Reidel U, Metz M, Maurer M, Hawro T.

Veröffentlicht im Journal of the American Academy of Dermatology im Oktober 2021

Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.

Amy S Paller, Andreas Wollenberg, Elaine Siegfried, Diamant Thaçi, Michael J Cork, Peter D Arkwright, Melinda Gooderham, Xian Sun, John T O'Malley, Faisal A Khokhar, Jignesh Vakil, Ashish Bansal, Karli Rosner, Brad Shumel, Noah A Levit

veröffentlicht im Pediatric Drugs im August 2021.

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.

Andrew Blauvelt, April W Armstrong, Richard G Langley, Kurt Gebauer, Diamant Thaçi, Jerry Bagel, Lyn C Guenther, Carle Paul, Bruce Randazzo, Susan Flavin, Ming-Chun Hsu, Yin You, Kristian Reich.

veröffentlicht im Journal of Dermatological Treatment im August 2021.

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.

Emma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, Kim A Papp, Aileen L Pangan, Andrew Blauvelt, Diamant Thaçi, Chia-Yu Chu, H Chih-Ho Hong, Norito Katoh, Amy S Paller, Brian Calimlim, Yihua Gu, Xiaofei Hu, Meng Liu, Yang Yang, John Liu, Allan R Tenorio, Alvina D Chu, Alan D Irvine.

veröffentlicht im The Lancet im Mai 2021.

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

Thomas Bieber, Eric L Simpson, Jonathan I Silverberg, Diamant Thaçi, Carle Paul, Andrew E Pink, Yoko Kataoka, Chia-Yu Chu, Marco DiBonaventura, Ricardo Rojo, Jeremias Antinew, Ileana Ionita, Rodney Sinclair, Seth Forman, Jacek Zdybski, Pinaki Biswas, Bimal Malhotra, Fan Zhang, Hernan Valdez, JADE COMPARE Investigators

veröffentlicht im The New England Journal of Medicine im März 2021.

The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study

Hawro T, Przybyłowicz K, Spindler M, Hawro M, Steć M, Altrichter S, Weller K, Magerl M, Reidel U, Alarbeed E, Alraboni O, Maurer M, Metz M.

Veröffentlicht im Journal of the American Academy of Dermatology im März 2021.

12/15-Lipoxygenase choreographs the resolution of IgG-mediated skin inflammation

Sezin T, Ferreirós N, Jennrich M, Ochirbold K, Seutter M, Attah C, Mousavi S, Zillikens D, Geisslinger G, Sadik CD.

Veröffentlicht im Journal of Autoimmunity im Dezember 2020

Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).

Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, Monika Liljedahl, Charles Lynde, Marie Holst Mørch, Kim A Papp, Jean-Luc Perrot, Linda Stein Gold, Amrit Takhar, Diamant Thaçi, Richard B Warren, Andreas Wollenberg.

veröffentlicht im Journal of the American Academy of Dermatology im September 2020.

Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line

Vorobyev A*, Gupta Y*, Sezin T*, Koga H, Bartsch YC, Belheouane M, Künzel S, Sina C, Schilf P, Körber-Ahrens H, Beltsiou F, Lara Ernst A, Khil'chenko S, Al-Aasam H, Manz RA, Diehl S, Steinhaus M, Jascholt J, Kouki P, Boehncke WH, Mayadas TN, Zillikens D, Sadik CD, Nishi H, Ehlers M, Möller S, Bieber K, Baines JF, Ibrahim SM, Ludwig RJ.

Veröffentlicht in Nature Communications im September 2019.

Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease

Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM, Schmidt E, Meshrkey F, Mousavi S, Zillikens D, Nunn MA, Sadik CD.

Veröffentlicht in JCI Insight im August 2019.

Comparison and interpretability of the available urticaria activity scores

Hawro T, Ohanyan T, Schoepke N, Metz M, Peveling-Oberhag A, Staubach P, Maurer M, Weller K.

Veröffentlicht in Allergy im Januar 2018

The Urticaria Activity Score-Validity, Reliability, and Responsiveness

Hawro T, Ohanyan T, Schoepke N, Metz M, Peveling-Oberhag A, Staubach P, Maurer M, Weller K.

Veröffentlicht im Journal of Allergy and Clinical Immunology im Juli-August 2018

Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis

Hawro M, Maurer M, Weller K, Maleszka R, Zalewska-Janowska A, Kaszuba A, Gerlicz-Kowalczuk Z, Hawro T.

Veröffentlicht im Journal of the American Academy of Dermatology im April 2017

Skin provocation tests may help to diagnose atopic dermatitis

Hawro T, Lehmann S, Altrichter S, Fluhr JW, Zuberbier T, Church MK, Maurer M, Metz M.

Veröffentlicht in Allergy im Dezember 2016

ptRNApred: computational identification and classification of post-transcriptional RNA

Gupta Y, Witte M, Möller S, Ludwig RJ, Restle T, Zillikens D, Ibrahim SM.

Veröffentlicht im Nucleic Acids Research im Dezember 2014

Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge

Hawro T, Saluja R, Weller K, Altrichter S, Metz M, Maurer M.

Veröffentlicht in Allergy im Januar 2014